MY174912A - Non-replicating virus-derived particles and uses thereof - Google Patents

Non-replicating virus-derived particles and uses thereof

Info

Publication number
MY174912A
MY174912A MYPI2015702052A MYPI2015702052A MY174912A MY 174912 A MY174912 A MY 174912A MY PI2015702052 A MYPI2015702052 A MY PI2015702052A MY PI2015702052 A MYPI2015702052 A MY PI2015702052A MY 174912 A MY174912 A MY 174912A
Authority
MY
Malaysia
Prior art keywords
derived particles
replicating virus
cells
replicating
derived particle
Prior art date
Application number
MYPI2015702052A
Other languages
English (en)
Inventor
David Conrad
Cory Batenchuk
Fabrice Leboeuf
John Cameron Bell
Original Assignee
Ottawa Hospital Res Inst
Celverum Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50977496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY174912(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ottawa Hospital Res Inst, Celverum Inc filed Critical Ottawa Hospital Res Inst
Publication of MY174912A publication Critical patent/MY174912A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20263—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MYPI2015702052A 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof MY174912A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740856P 2012-12-21 2012-12-21
US201361835310P 2013-06-14 2013-06-14

Publications (1)

Publication Number Publication Date
MY174912A true MY174912A (en) 2020-05-21

Family

ID=50977496

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015702052A MY174912A (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof

Country Status (17)

Country Link
US (2) US11110138B2 (enExample)
EP (1) EP2935569B1 (enExample)
JP (2) JP6612619B2 (enExample)
KR (1) KR102167497B1 (enExample)
CN (1) CN105121636A (enExample)
AU (1) AU2013362761B2 (enExample)
BR (1) BR112015015045A8 (enExample)
CA (1) CA2896162C (enExample)
CL (1) CL2015001738A1 (enExample)
ES (1) ES2745599T3 (enExample)
IL (1) IL239486B (enExample)
MX (1) MX376266B (enExample)
MY (1) MY174912A (enExample)
PH (1) PH12015501442A1 (enExample)
RU (1) RU2705556C2 (enExample)
SG (2) SG10201704903YA (enExample)
WO (1) WO2014094182A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896162C (en) * 2012-12-21 2021-10-12 Ottawa Hospital Research Institute Non-replicating virus-derived particles and uses thereof
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN109985244A (zh) * 2017-12-29 2019-07-09 广州威溶特医药科技有限公司 E3连接酶抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109432098B (zh) * 2018-11-20 2021-04-13 天津大学 化合物ps-341在制备小rna病毒科肠道病毒属病毒抑制剂的应用
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
IL153570A0 (en) 2000-06-26 2003-07-06 Wellstat Biologics Corp Purging of cells using viruses
AU2003268505A1 (en) * 2002-09-09 2004-03-29 University Of Tennessee Research Foundation Recombinatant mutants of rhabdovirus and methods of use thereof
JP4708027B2 (ja) 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
EP2301573A1 (en) 2002-10-01 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Anti-cancer and anti-infectious disease compositions and methods for using same
ES2319424T3 (es) 2003-03-27 2009-05-07 Ottawa Health Research Institute Virus mutantes de la estomatitis vesivular y sus usos.
EP1726647B1 (en) * 2004-03-19 2015-01-07 GenomIdea, Inc. Gene promoting vascular endothelial cell growth
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
CA2921063C (en) 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
ES2532808T3 (es) 2008-09-16 2015-03-31 Genomidea Inc. Agente terapéutico/profiláctico para cáncer de próstata
CN102858959B (zh) 2009-12-10 2016-02-24 渥太华医院研究院 溶瘤弹状病毒
RU2013139565A (ru) 2011-01-27 2015-03-10 Лентиджен Корпорейшн Усовершенствованная праймерная и бустерная вакцина
CN103415797B (zh) * 2011-02-02 2016-01-27 康宁光缆系统有限责任公司 适用于为设备机架中的光学底板建立光学连接的稠密光纤连接器总成及相关的连接器与缆线
WO2012122649A1 (en) 2011-03-15 2012-09-20 Ottawa Hospital Research Institute Recombinant orf virus
US9623096B2 (en) * 2011-11-09 2017-04-18 Celverum Inc. Virally infected hematopoietic cells and uses thereof
CA2896162C (en) * 2012-12-21 2021-10-12 Ottawa Hospital Research Institute Non-replicating virus-derived particles and uses thereof

Also Published As

Publication number Publication date
US11110138B2 (en) 2021-09-07
US20210346441A1 (en) 2021-11-11
JP2020014467A (ja) 2020-01-30
RU2705556C2 (ru) 2019-11-07
CN105121636A (zh) 2015-12-02
IL239486B (en) 2019-08-29
AU2013362761A1 (en) 2015-07-16
EP2935569B1 (en) 2019-05-01
HK1210624A1 (en) 2016-04-29
EP2935569A1 (en) 2015-10-28
KR20150112957A (ko) 2015-10-07
WO2014094182A1 (en) 2014-06-26
SG11201504843UA (en) 2015-07-30
NZ709439A (en) 2020-09-25
JP2016501538A (ja) 2016-01-21
KR102167497B1 (ko) 2020-10-20
MX376266B (es) 2025-03-07
US20150320810A1 (en) 2015-11-12
PH12015501442A1 (en) 2015-09-14
CL2015001738A1 (es) 2015-12-18
BR112015015045A8 (pt) 2018-01-23
JP6612619B2 (ja) 2019-11-27
RU2015128766A (ru) 2017-01-26
CA2896162A1 (en) 2014-06-26
MX2015008155A (es) 2016-02-05
ES2745599T3 (es) 2020-03-02
EP2935569A4 (en) 2016-08-03
IL239486A0 (en) 2015-07-30
SG10201704903YA (en) 2017-07-28
CA2896162C (en) 2021-10-12
AU2013362761B2 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
PH12015501442A1 (en) Non-replicating virus-derived particles and uses thereof
EP3697820A4 (en) PROCEDURES AND COMPOSITIONS RELATED TO MANIPULATED REGULATORY T-CELLS
MX2016008494A (es) Articulo abrasivo que incluye partículas abrasivas perfiladas.
MX362413B (es) Particula de suministro que contiene agente benefico con base en copolimero de estireno anhidrido maleico.
MX369660B (es) Particulas precipitadas de carbonato de calcio y uso de las mismas.
PH12014501852B1 (en) Sunscreen composition
MX2016013468A (es) Articulo abrasivo que incluye particulas abrasivas conformadas.
MX2015017782A (es) Articulo abrasivo que incluye particulas abrasivas moldeadas.
MX2015017794A (es) Articulo abrasivo que incluye particulas abrasivas conformadas.
EP2959031A4 (en) Coatings and composites including inorganic fullerene-like particles and inorganic tubular-like particles
MX380058B (es) Material mineral en polvo con elevada capacidad de dispersion, y uso del material mineral en polvo.
IL288233A (en) Modified viral particles and their use
EP3074376A4 (en) Particle suspensions of flocculating polymer powders and powder flocculant polymer blends
EP3039049A4 (en) Self-crosslinkable polymer and aqueous dispersion comprising particles of the same
TW201637267A (en) Powder, electrode and battery comprising such a powder
GB2492265A (en) Hydraulic lime composition
SG11201702316SA (en) Monolayer of pbmcs or bone-marrow cells and uses thereof
EP3143162A4 (en) Mirna expression signature in the classification of thyroid tumors
WO2012035283A8 (en) Pharmaceutical composition
IL251814A0 (en) Non-amphoteric, quaternizable and water-soluble polymers for changing the surface charge of solid particles
EP3357934B8 (en) Polymer particles and use thereof
EP3102613A4 (en) Polymer particles and uses thereof
GB201210060D0 (en) Composition
EP3036285A4 (en) Particle suspensions of flocculating polymer powders
EP3039162A4 (en) Determination of immune cells and other cells